Navigating the Complexity: Acute on Chronic Pelvic Inflammatory Disease (PID)

(English) Pelvic inflammatory disease (PID) is a syndrome that predominately affects cisgender women of reproductive age and can lead to chronic pelvic pain and infertility. Endometritis, salpingitis, tubo-ovarian abscess, and pelvic peritonitis are all on the spectrum of inflammatory processes comprising PID. The basic aim of the study is to effectively manage and treat acute on chronic pelvic inflammatory disease (PID) to prevent early complications. A 32-year-old woman, gravida 2 para 2 (P2L2), with a history of two previous lower segment cesarean sections (LSCS), presented with complaints of abdominal pain and heavy menstrual bleeding for the past 5 years. These symptoms worsened significantly over the last 2 days, accompanied by fever, vomiting and generalised weakness. PID is mostly diagnosed clinically. Imaging has a limited role. Surgical management is the treatment of choice with repeated exacerbations of PID. The extensive pelvic pathology identified on imaging, coupled with her systemic signs of sepsis, indicates the need for aggressive and comprehensive treatment. This case highlights the importance of timely diagnosis and management of PID to prevent complications such as infertility, chronic pelvic pain, and systemic infections. Files IJPCR,Vol16,Issue10,Article160.pdf Files (3.6 MB) | Name | Size | Download all | |---|---|---| | md5:1df3f1af3d2976bac369084c9edf7149 | 3.6 MB | Preview Download | Additional details Dates - Accepted - 2024-09-26 Software - Repository URL - http://impactfactor.org/PDF/IJPCR/16/IJPCR,Vol16,Issue10,Article160.pdf - Development Status - Active

- 1. Hillier SL, Bernstein KT, Aral S. A Review of the Challenges and Complexities in the Diagnosis, Etiology, Epidemiology, and Pathogenesis of Pelvic Inflammatory Disease. J Infect Dis. 2021 Aug 16; 224(12 Suppl 2):S23-S28. doi: 10.1093/infdis/jiab116. PMID: 34396398; PMCID: PMC8365114. 2. Rock, J. A., & Jones, H. W., III (Eds.). (2008). Te Linde's Operative Gynecology (10th ed.). Lippincott Williams & Wilkins. 3. Haggerty CL, Ness RB, Totten PA, et al. Presence and concentrations of select bacterial vaginosis-associated bacteria are associated with increased risk of pelvic inflammatory disease. Sex Transm Dis 2020; 47:344–6 4. Lis R, Rowhani-Rahbar A, Manhart LE. Mycoplasma genitalium infection and female reproductive tract disease: a meta-analysis. Clin Infect Dis. 2015; 61(3):418-26. 5. Møller BR, Taylor-Robinson D, Furr PM, Freundt EA. Acute upper genital-tract disease in female monkeys provoked experimentally by Mycoplasma genitalium. Br J Exp Pathol. 1985; 66(4):417-26. 6. Pierce AM, Hart CA. Vulvovaginitis: causes and management. Arch Dis Child. 1992; 67(4):509-12. 7. Barham WB, Haberberger RL, Decker CF. Group A streptococcal sepsis secondary to acute salpingitis. Clin Infect Dis. 1993; 16(3):444-5. 8. Workowski KA, Bolan GA; Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep. 2015; 64(3):1-137. 9. Soper DE, Wiesenfeld HC. The continued challenges in the diagnosis of acute PID: focus on clinically mild disease. J Infect Dis. 2021;224(Suppl 2) 10. Ness RB, Soper DE, Holley RL, et al. Effectiveness of inpatient and outpatient treatment strategies for women with pelvic inflammatory disease: results from the Pelvic Inflammatory Disease Evaluation and Clinical Health (PEACH) Randomized Trial. Am J Obstet Gynecol. 2002; 186(5):929-37. 11. Hillier SL, Meyn MA, Avolia H, et al. Lower genital tract predictors of acute endometritis among women with signs and symptoms of pelvic inflammatory disease. Sex Transm Infect. 2019;95 12. Zheng X, O'Connell CM, Zhong W, et al. Discovery of blood transcriptional endotypes inwomen with pelvic inflammatory disease. J Immunol. 2018; 200(8):2941-56. 13. Rahman KS, Kaltenboeck B. Multi-peptide assays for sensitive and differential detection of anti-Chlamydia trachomatis antibodies. J Infect Dis. 2021;224(Suppl 2) 14. Rahman KS, Darville T, Russell AN, et al. Comprehensive molecular serology of human Chlamydia trachomatis infections by peptide enzyme-linked immunosorbent assays. mSphere. 2018;3(3) 15. Rahman KS, Darville T, Wiesenfeld HC, et al. Mixed Chlamydia trachomatis peptide antigens provide a specific and sensitive single-well colorimetric enzyme-linked immunosorbent assay for detection of human anti-C. Trachomatis antibodies. mSphere. 2018;3(5) 16. Russell MW. Immune responses to Neisseria gonorrhoeae: challenges and opportunities with respect to pelvic inflammatory disease. J Infect Dis. 2021;224(Suppl 2) 17. Buchanan TM, Eschenbach DA, Knapp JS, Holmes KK. Gonococcal salpingitis is less likely to recur with Neisseria gonorrhoeae of the same principal outer membrane protein antigenic type. Am J Obstet Gynecol. 1980; 138(8):978-80. 18. Plummer FA, Simonsen JN, Chubb H, et al. Epidemiologic evidence for the development of serovar-specific immunity after gonococcal infection. J Clin Invest. 1989; 83(5):1472-6. 19. Liu Y, Islam EA, Jarvis GA, Gray-Owen SD, Russell MW. Neisseria gonorrhoeae selectively suppresses the development of Th1 and Th2 cells, and enhances Th17 cell responses, through TGF-β-dependent mechanisms. Mucosal Immunol. 2012; 5(3):320-31. 20. Connolly KL, Pilligua-Lucas M, Gomez C, et al. Advances in animal modeling for preclinical testing of vaccines and therapeutics against gonococcal pelvic inflammatory disease. J Infect Dis. 2021.